No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Buy Rating for Silexion Therapeutics Driven by Promising SIL-204 Developments and Market Expansion
Express News | Silexion Therapeutics Corp - to Conduct Additional Toxicology and Pharmacodynamic Studies in 2025
Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data
Maxim Group Maintains Silexion Therapeutics(SLXN.US) With Buy Rating, Maintains Target Price $5
Silexion Announces Completion Of SIL204 Development Plan For KRAS Cancers; Presentation Scheduled At NeauxCancer 2025 Conference In New Orleans
Maxim Group Maintains Silexion Therapeutics(SLXN.US) With Buy Rating, Cuts Target Price to $5
